Medifast (NYSE: MED) Q3 2026 Earnings: Narrower Loss, Revenue Beat Amidst GLP-1 Competition
Medifast reported a narrower Q3 2026 loss of $0.19 per share and revenue of $72.00 million, both exceeding analyst estimates. Despite the revenue beat, the company faced a 19.4% revenue drop year-over-year and a significant decline in active coaches (from 19,500 to 10,200), partly attributed to…